We are pleased to announce the publication of The Max Foundation’s 2019 Annual Report, showcasing the variety of achievements made possible with the support of our dedicated donors, partners, and global team.
“Looking back at 2019 a common theme stands out: reaching new frontiers,” write The Max Foundation CEO Pat Garcia-Gonzalez and The Max Foundation Board President Paula Boultbee in the report.
These new frontiers include our program’s expansion into Mozambique, where chronic myeloid leukemia (CML) patients gained access to lifesaving treatment for the first time. We also grew our access to diagnostics initiatives that allowed patients to have access to affordable and local molecular tests. And through our patient services, we connected with thousands of patients and their caregivers worldwide through one-on-one support and community outreach.
In this report, we celebrate our organization’s achievements as well as patients’ milestones—each with a unique journey toward accessing treatment and care.
We’re thrilled to share with you the significance of our growth into new frontiers, and the impact it’s had on the patients we support worldwide. We hope you see yourself in each of our achievements and feel how your support directly contributes to the lives of patients and families who are now able to face their cancer with dignity and hope.
The Max Foundation (Max) is a global health nonprofit organization dedicated to accelerating health equity. For more than 25 years, Max has pioneered practical, scalable, high-quality solutions to bring lifesaving treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope. Learn more at www.themaxfoundation.org
In a recent commentary published in the Journal of Global Oncology, co-authors Pat Garcia-Gonzalez MA, Gilberto Lopes MD, Erin Schwartz and Lawrence Shulman MD, clearly outline the need and efficacy of humanitarian donation programs using lessons learned from the success of joint access initiatives between Novartis and The Max Foundation.
In 2017 The Max Foundation, through its subsidiary MaxAid, and Novartis have renewed their commitment to patients by launching CMLPath to Care™ a new collaboration aimed at providing humanitarian access to treatment for CML and other rare cancers for those patients for whom no other form of local treatment access exists today. CMLPath to Care consists of humanitarian product donations and funding support from Novartis to Max, and an innovative new distribution model developed and implemented by Max and its international distributor, under the Max Access Solution umbrella.
The Max Foundation is proud to announce that our Chief Executive Officer Pat Garcia-Gonzalez has been named a finalist for the Union for International Cancer Control (UICC)’s CEO Award!
